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INTRODUCTION
A total of 221,347 new cancers and 82,344 deaths from cancer 
were predicted to occur in Korea in 2019 based on data from 
the Korea Central Cancer Registry and the Korea National 
Cancer Incidence Database from 1993 to 2018. In 2019, breast 
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Since April 2015, post-mastectomy breast reconstruction has been covered by the Korean 
National Health Insurance Service (NHIS). The frequency of these procedures has increased 
very rapidly. We analyzed data obtained from the Big Data Hub of the Health Insurance Re-
view and Assessment Service (HIRA) and determined annual changes in the number of breast 
reconstruction procedures and related trends in Korea. We evaluated the numbers of mastec-
tomy and breast reconstruction procedures performed between April 2015 and December 
2018 using data from the HIRA Big Data Hub. We determined annual changes in the numbers 
of total, autologous, and implant breast reconstructions after NHIS coverage commenced. 
Data were analyzed using Microsoft Excel. The post-mastectomy breast reconstruction rate 
increased from 19.4% in 2015 to 53.4% in 2018. In 2015, implant reconstruction was per-
formed in 1,366 cases and autologous reconstruction in 905 (60.1% and 39.8%, respectively); 
these figures increased to 3,703 and 1,570 (70.2% and 29.7%, respectively) in 2018. Free tis-
sue transfer and deep inferior epigastric perforator flap creation were the most common au-
tologous reconstruction procedures. For implant-based reconstructions, the rates of direct-
to-implant and tissue-expander breast reconstructions (first stage) were similar in 2018. This 
study summarizes breast reconstruction trends in Korea after NHIS coverage was expanded in 
2015. A significant increase over time in the post-mastectomy breast reconstruction rate was 
evident, with a trend toward implant-based reconstruction. Analysis of data from the HIRA 
Big Data Hub can be used to predict breast reconstruction trends and convey precise infor-
mation to patients and physicians.
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cancer was predicted to account for 23.8% (n = 24,010) of all 
cancers in women, a value almost four times higher than that of 
20 years ago. Currently, breast cancer is the most common ma-
lignancy in women [1]. Although the cause of the increased in-
cidence of breast cancer remains unclear, an increase in the total 
duration of estrogen exposure is associated with consumption 
of a Westernized diet, obesity, late marriage, a low fertility rate, 
decreased breastfeeding, early menarche, and late menopause 
[2]. Deaths from breast cancer in 2019 were expected to ac-
count for 8.5% of deaths (n = 2,719) from all cancers in women. 
The mortality rate of breast cancer is relatively low compared to 
those of other cancers, likely due to early cancer detection by 
Korea National Breast Cancer Screening Program [3]. 
The incidence of partial mastectomy (27.9% in 2000) has 
steadily increased, overtaking total mastectomy in 2006 and 
reaching 67.2% by 2012. The rate of partial mastectomy fell to 
64.9% in 2014 and 61.6% in 2016, while the rate of total mastec-
tomy rose to 34.0% in 2014 and 37.0% in 2016. The partial 
mastectomy rate has been decreasing since 2013, as advanced 
breast cancer requires total mastectomy, and developments in 
imaging modalities such as magnetic resonance imaging have fa-
cilitated the diagnosis of less advanced breast cancers [2]. 
For breast cancer patients, breast reconstruction affords es-
thetic and psychological benefits and improves quality of life 
[4,5]. Despite these benefits and a recent increase in favorable 
perceptions of breast reconstruction, the high cost of surgery 
and the lack of insurance coverage constitute major barriers to 
breast reconstruction after mastectomy. In the United States, the 
Women’s Health and Cancer Rights Act (WHCRA), which 
mandates insurance coverage of all post-mastectomy breast re-
constructions, was signed into law in October 1998 and enacted 
in January 1999 [6].
The South Korean health insurance system is a public single-
payer system; healthcare providers are automatically eligible for 
this system and must treat patients using covered healthcare ser-
vices. The private sector invests in the system, but the govern-
ment controls it [7]. Breast reconstruction after total mastecto-
my has been covered by the National Health Insurance Service 
(NHIS) since April 2015, at which point the Health Insurance 
Review and Assessment Service (HIRA) began to collect com-
prehensive data on breast reconstructions. This policy change 
encouraged breast reconstruction after total mastectomy, and 
over half of all mastectomy patients underwent breast recon-
struction in 2018.
We explored the status of and trends in post-mastectomy 
breast reconstruction after insurance coverage was initiated in 
2015 by analyzing data stored in the HIRA Big Data Hub. By 
doing so, we created a standardized data profile of breast recon-
struction in Korea.
METHODS
We evaluated the numbers of mastectomy and breast recon-
struction procedures performed between April 2015 and De-
cember 2018. The study was approved by the Institutional Re-
view Board of Soonchunhyang University Hospital. We were 
provided online access to the HIRA Big Data Hub, and we col-
lected data using the procedural codes for mastectomy and 
breast reconstruction from the Korean Standard Classification 
of Diseases, seventh revision. Autologous breast reconstruction 
was classified as LD, PTRAM, or FTRAM (defined below). 
The flaps employed included latissimus dorsi (LD) muscle 
flaps, muscle-sparing LD myocutaneous flaps (thoracodorsal 
artery perforator flaps), and extended LD myocutaneous flaps. 
The PTRAM category included both single-pedicled transverse 
rectus abdominis musculocutaneous (TRAM) flaps and biped-
icled TRAM flaps. The FTRAM category included free TRAM 
flaps, muscle-sparing FTRAM flaps, and deep inferior epigastric 
artery perforator (DIEP) free flaps. Implant breast reconstruc-
tion was classified as either tissue expander (TE; the first stage 
of two-stage breast reconstruction) or direct-to-implant (DTI) 
(Table 1). The exclusion criteria were (1) male sex, (2) nipple-
areolar complex reconstruction, (3) code N7150 (implant 
based-expander addition to a permanent breast implant, which 
is the second stage of two-stage breast reconstruction), and be-
nign cases (codes N7131 and N7133). Partial mastectomy cases 
(codes N7136 and N7137) were included; however, the patient 
populations differed because insurance coverage of breast re-
construction is available only to patients who undergo total 
mastectomy. Thus, the mastectomy breast reconstruction rates 
refer only to patients undergoing breast reconstruction after to-
tal mastectomy. Data were gathered by medical practice catego-
ry and procedural code and were categorized as mastectomy or 
as autologous breast or implant reconstruction. Medical practice 
statistics were prepared with reference to medical costs request-
ed by healthcare institutions in 2010.
We evaluated the annual changes in the numbers of mastecto-
mies and breast reconstructions (both autologous and implant 
reconstructions) and patient age distribution from 2015 to 
2018. In July 2017, the mastectomy procedural codes were 
changed from N7130 (radical mastectomy without axillary 
lymph node dissection [ALND]), N7131 (simple mastecto-
my), N7133 (partial mastectomy), and N7135 (radical mastec-
tomy) to N7136 (partial mastectomy with ALND), N7137 
(partial mastectomy without ALND), N7138 (total mastecto-
my with ALND), and N7139 (total mastectomy without 
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ALND).
All data were analyzed using Microsoft Excel (Microsoft 
Corp., Redmond, WA, USA).
RESULTS
We examined all data regarding mastectomy and breast recon-
struction procedures performed between April 2015 and De-
cember 2018. The total number of mastectomy procedures (sim-
ple, partial, and total) increased from 21,756 in 2015 to 34,072 in 
2018, constituting approximately a 56.6% increase. Simple (be-
nign) and partial mastectomies increased from 10,038 in 2015 to 
24,212 in 2018. Total mastectomies decreased from 11,718 in 
2015 to 9,860 in 2018 (Fig. 1).
The rate of post-mastectomy breast reconstruction increased 
from 19.4% in 2015 to 53.4% in 2018 (Fig. 2). In 2015, there 
were 1,366 cases of implant reconstruction and 905 cases of au-
Code Procedure Categorization
N7130 Radical mastectomy (including modified radical 
mastectomy and radical BCS operations; without 
ALND)
N7131 Simple mastectomy (benign)
N7133 Partial mastectomy (benign)
N7135 Radical mastectomy (including modified radical 
mastectomy and radical BCS operations)
N7136 Partial mastectomy (with ALND)
N7137 Partial mastectomy (without ALND)
N7138 Total mastectomy (with ALND)
N7139 Total mastectomy (without ALND) 
N7140 Autologous-LD flap LD
N7141 Autologous-muscle-sparing LD myocutaneous flap 
(TDAP)
LD
N7142 Autologous-extended LD myocutaneous flap LD
N7143 Autologous-pedicled TRAM flap PTRAM
N7144 Autologous-bipedicled TRAM flap PTRAM
N7145 Autologous-transverse TRAM free flap FTRAM
N7146 Autologous-muscle sparing TRAM free flap FTRAM
N7147 Autologous-DIEP FTRAM
N7148 Implant based-expander insertion (2 stage breast 
reconstruction, first stage) 
TE
N7149 Implant based-DTI DTI
BCS, breast-conserving surgery; ALND, axillary lymph node dissection; LD, 
latissimus dorsi; TDAP, thoracodorsal artery perforator; TRAM, transverse rectus 
abdominis musculocutaneous; PTRAM, single-pedicled TRAM flap and bipedicled 
TRAM flap; FTRAM, free TRAM flap, muscle-sparing TRAM flap, and DIEP free 
flap; DIEP, deep inferior epigastric artery perforator; TE, tissue expander; DTI, 
direct-to-implant.
Table 1. Inclusion criteria for the present study: mastectomy 
and breast reconstruction procedural codes 
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Fig. 2. Annual changes in breast reconstruction
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tologous reconstruction (60.1% and 39.8% of total cases, re-
spectively); in 2018, these rates were 3,703 (70.2%) and 1,570 
(29.7%), respectively (Fig. 3). Of the 905 autologous recon-
struction cases in 2015, 298 (32.9%) featured placement of an 
LD flap, 198 (21.9%) involved placement of a PTRAM flap, and 
409 (45.2%) involved placement of FTRAM or DIEP flaps. Of 
the 1,570 such cases in 2018, these figures were 424 (27.0%), 
188 (11.9%), and 958 (61.0%), respectively (Fig. 4). FTRAM 
or DIEP flaps were preferred from 2015 to 2018. Of the 1,366 
implant-based reconstruction procedures conducted in 2015, 
777 (56.9%) were DTI reconstructions, while 589 (43.1%) 
were TE reconstructions (first stage). In 2018, these figures 
were 1,863 (50.3%) and 1,840 (49.7%), respectively (Fig. 5). 
The proportions of DTI and TE breast reconstructions (first 
stage) were thus similar in 2018.
Between 2015 and 2018, the predominant age group of pa-
tients undergoing breast reconstruction was 40–49 years (Table 
2), and the age distribution did not vary greatly over time. In 
2018, younger patients (30–39 years of age) preferred implant 
reconstruction (78.9%; autologous reconstructions, 22.1%). In 
older patients (60–69 years of age), autologous breast recon-
struction was somewhat more popular (implant reconstruc-
tions, 69.6%; autologous reconstructions, 30.4%) than in 
younger patients (Fig. 6). Patients under 20 years old and pa-
tients over 70 years old were excluded from the results due to 
Fig. 3. Breast reconstruction rate in Korea
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Fig. 4. Annual changes in autologous breast reconstruction
The number of autologous breast reconstruction procedures in Korea.
LD, latissimus dorsi muscle flap, muscle-sparing latissimus dorsi 
myocutaneous flap (thoracodorsal artery perforator flap), and ex-
tended latissimus dorsi myocutaneous flap; PTRAM, single-pedicled 
transverse rectus abdominis musculocutaneous flap and bipedicled 
transverse rectus abdominis musculocutaneous flap; FTRAM, free 
transverse rectus abdominis musculocutaneous flap, muscle-spar-
ing transverse rectus abdominis musculocutaneous flap, and deep 
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Fig. 5. Annual changes in implant breast reconstruction
The number of implant breast reconstruction procedures in Korea.
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Post-mastectomy breast reconstruction affords psychological, 
social, emotional, and functional improvements and enhances 
self-esteem, sexuality, and body image. Patients requiring breast 
reconstruction face complex decisions regarding reconstruction 
type and timing. In 2016, 37% of breast cancer patients under-
went total mastectomy, while only 23% underwent breast re-
construction [2]. In the early 2000s, when the total mastectomy 
rate was approximately 50%, fewer than 20% of eligible patients 
underwent breast reconstruction. In the United States, the fed-
eral WHCRA (enacted in 1998) guaranteed coverage of recon-
struction fees incurred after mastectomy [8]. It remains unclear 
whether the WHCRA has increased the rate of breast recon-
struction; however, a recent study reported a significant increase 
[9,10].
In Korea, breast reconstruction after total mastectomy has 
been covered by the NHIS since April 2015. Autologous and 
implant breast reconstructions, nipple-areolar complex recon-
structions, and additional operations required due to post-re-
construction complications or deformities are also covered 
[11]. Prior to April 2015, breast reconstruction numbers were 
low, as such procedures were considered primarily cosmetic.
Our work was rendered possible by our access to the HIRA 
Big Data Hub. HIRA is the sole nationwide third-party adminis-
trator that reviews health insurance claims, thereby assessing the 
functions of the Korean NHIS. HIRA is an independent agency. 
Individuals pay premiums to the NHIS and then receive health-
care services with only small copayments. Healthcare providers 
submit claims to HIRA, which reviews them and sends the re-
sults to both the NHIS and the providers. The NHIS then reim-
burses the providers. The HIRA database retains all claims 
made by the entire Korean population (50 million people) for a 
5-year period [12].
In the United States, relatively accurate data on breast recon-
struction are available for all years from 1998 (when the WH-
CRA took effect) onward; however, in Korea, most earlier 
breast reconstruction studies relied on retrospective surveys or 
small clinical samples. The HIRA data collected since April 
2015 are highly accurate and reliable.
The Plastic Surgery Statistics Report (2018) published by the 
American Society of Plastic Surgeons stated that the numbers of 
breast reconstruction procedures in the United States in 2000, 
2017, and 2018 were 78,832, 106,295, and 101,657 respectively, 
reflecting an increase of 29% from 2000 to 2018 but a decrease 
of 4% from 2017 to 2018 [13]. In the United States, the approx-
imate post-mastectomy breast reconstruction rate is 40%. A 
study of general surgeons treating a population-based sample of 
1,844 women diagnosed with breast cancer in 2002 found that 
only 24% of surgeons referred more than 75% of their mastecto-
my patients to plastic surgeons before surgery [14]. In Korea, 
the numbers of breast reconstruction procedures in 2015 and 
Year
Age (yr) 
30–39 40–49 50–59 60–69
2015 335 (15) 1,011 (47)  700 (32) 126 (6)
2016 812 (17) 2,352 (48) 1,386 (29) 291 (6)
2017 690 (17) 2,025 (49) 1,230 (30) 181 (4)
2018 852 (16) 2,414 (47) 1,510 (29) 392 (8)
Values are presented as number (%).
Table 2. Numbers of breast reconstruction cases by age group 
from 2015 to 2018
Fig. 6. Breast reconstruction procedures performed in 2018
LD, latissimus dorsi muscle flap, muscle-sparing latissimus dorsi myocutaneous flap (thoracodorsal artery perforator flap), and extended latissi-
mus dorsi myocutaneous flap; DIEP+TRAM, single-pedicled transverse rectus abdominis musculocutaneous flap, bipedicled transverse rectus ab-
dominis musculocutaneous flap, free transverse rectus abdominis musculocutaneous flap, muscle-sparing transverse rectus abdominis musculo-
cutaneous flap, and deep inferior epigastric artery perforator (DIEP) free flap; TE, tissue expander; DTI, direct-to-implant.
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2018 were 2,271 and 5,273, respectively, constituting a 132% 
increase. 
In Korea, the breast reconstruction rate after total mastectomy 
increased from 19% to 53% from 2015 to 2018. Today, more 
than half of all Korean total mastectomy patients undergo breast 
reconstruction, both because reconstruction is now covered by 
the NHIS and because oncological care patterns are changing. 
Other factors may also be involved. First, we found that the sta-
tistics for total mastectomy patients were inaccurate. In July 
2017, the procedural codes for mastectomy changed, but accu-
rate data for all mastectomy patients remained available. Previ-
ously, there was a tendency to overestimate the numbers of total 
mastectomy procedures because the procedural codes for total 
and partial mastectomy were often confused. Second, the num-
ber of patients undergoing total mastectomy is decreasing, while 
the number undergoing partial mastectomy is increasing. As 
only breast reconstructions after total mastectomy are included 
in the HIRA Big Data Hub, the reconstruction rate may be high-
er if reconstructions after partial mastectomy were included.
 Currently, autologous breast reconstruction favors the use of 
FTRAM and DIEP flaps (61% of all reconstructions); the fig-
ure is similar in the United States (Plastic Surgery Statistics Re-
port 2018; American Society of Plastic Surgeons), at about 
60%. However, the LD flap was the third most-preferred flap in 
Korea (12%), followed by the PTRAM flap, whereas the LD 
flap was the second most-preferred flap in the United States 
(30%) [13]. 
 In both countries, implant reconstruction is more popular 
than autologous reconstruction. In Korea in 2018, the implant 
reconstruction rate had increased to 70%, while that in the Unit-
ed States was 82%. Although implant reconstruction was clearly 
preferred in both Korea and the United States, the frequency by 
type differed. In Korea, the percentages of DTI and TE recon-
structions in 2015 were 57% and 43%, respectively, but by 2018, 
the proportion of TE reconstructions had increased to 50%. In 
the United States, the percentages of DTI and TE reconstruc-
tions in 2018 were 16% and 84%, respectively [13]. The prefer-
ence for implant reconstruction has been analyzed elsewhere. 
Regulatory surveillance of silicone breast implants by the U.S. 
Food and Drug Administration has allayed safety concerns [15]. 
Other reasons for choosing implants are the shorter recovery 
time, absence of a donor site scar, and overall surgical impact. 
Patients choosing implants seek restoration of the total body 
image [16]. The social view of beauty has also changed, and 
women now prefer non-ptotic implants over more natural-ap-
pearing autologous reconstruction. Through the increased utili-
zation of implants in post-mastectomy radiation settings, the use 
of implants has been shown to be acceptable [17]. Changes in 
oncological practice have also expanded implant breast recon-
struction. Bilateral mastectomies are now more common than 
before, as contralateral prophylactic mastectomy is favored. This 
increases the deformity, the need for breast reconstruction, and 
consequently the need for implants [18]. 
 In terms of breast reconstruction rates by age, 48% of all pa-
tients who underwent breast reconstruction in Korea were 
women aged 40–49 years; in the United States, the correspond-
ing proportion was 50% [13]. The incidence of breast cancer in 
women aged 40–49 years is the highest among all age groups. In 
December 2010, the proportion of premenopausal women with 
breast cancer was higher than that of postmenopausal women. 
However, in 2015, postmenopausal breast cancer accounted for 
53.5% of all breast cancers. The prevalence of breast cancer in 
premenopausal women is gradually decreasing, but the preva-
lence of breast cancer in postmenopausal women is increasing 
[2]. Thus, the total mastectomy rate was highest in those aged 
40–49 years, which seems to have impacted the breast recon-
struction statistics. The younger the patient, the less likely she is 
to prefer autologous breast reconstruction; donor site adiposity 
may be inadequate, and the long recovery time, donor-site mor-
bidity, and scarring are perceived as major detractions [16].
 Women over 60 years old accounted for 26% of all mastecto-
mies in 2018; of these women, only 7% underwent breast re-
construction. The autologous reconstruction rate was higher 
than that in younger women. The determinants of reconstruc-
tion-related decision-making in elderly patients have been stud-
ied. Appropriate timing and the quality of information imparted 
by the surgeon were major modifiable factors that improved ac-
cess to breast reconstruction [19]. 
Our work has several limitations. First, we lacked accurate data 
on post-mastectomy breast reconstruction numbers prior to 
April 2015, when NHIS coverage expanded. A thorough evalu-
ation of raw data from every Korean hospital is required. Also, 
since only data from April 2015 onward are available for analy-
sis, our data were not representative of the entire year of 2015. 
Second, the HIRA Big Data Hub registry does not distinguish 
between immediate and delayed reconstruction. As delayed re-
construction cannot be linked to the year of the mastectomy, we 
reported only immediate reconstructions. Third, additional 
procedures, such as fat grafting or placement of acellular dermal 
matrix, are not reported here. Future multicenter studies and 
surveys are required to overcome these limitations.
CONCLUSIONS
The present study provides an overview of trends regarding 
breast reconstruction in Korea. We assessed annual changes af-
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ter expansion of NHIS coverage in April 2015. An increasing 
frequency of post-mastectomy breast reconstruction procedures 
was evident, with a predominant trend toward implant breast 
reconstruction. Analysis of breast reconstruction statistics using 
the HIRA Big Data Hub is helpful in predicting breast recon-
struction trends and provides useful information to patients. 
Our results indicate that NHIS coverage of breast reconstruc-
tion has led to annual increases in the breast reconstruction rate.
NOTE
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